What is Pulmozyme?

What is Pulmozyme?

Pulmozyme®(dornase alfa) is indicated for the management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted and over 5 years of age to improve pulmonary function.1

Consider Pulmozyme for the management of cystic fibrosis.
An agent with a distinct mechanism of action in helping to clear mucus 1, 3-6

Countries where Pulmozyme is approved

Pulmozyme is approved in > 65 countries. Please see the map below for further information.

1. Pulmozyme SmPC, Electronic Medicines Compendium, accessed 10/8/18

3. Harms  HK et al. Dnase International Study Group. Multicenter, open-label study of recombinant human Dnase in cystic fibrosis patients with moderate lung disease. Pediatr Pulmonol. 1998; 23(3): 155-161.

4. King, M. Mucolytics and mucus clearance. In Rubin BK, van der Sxhans CP, eds. Therapy for Mucus-Clearance Disorders. New Yoirk, NY: Marcel Dekker Inc, 2004:201-224. 

5. Chmiel, JF, Kanstan MW. Anti-inflammatory medication for cystic fibrosis lung disease: selecting the most appropriate agent. Treat Respir Med. 2005; 4(4):255-273.

6. Puchelle E et al. Physical and functional properties of airway secretions in cystic fibrosis – therapeutic approaches. Respiration. 1995; 62(suppl 1) 2-12.

35. The Pharma Letter. EU gives go-ahead to Pulmozyme. https://www.thepharmaletter.com/article/eu-gives-go-ahead-to-pulmozyme. Accessed March 29, 2017